Skip to content

Inspection Record

Titan Kogyo, Ltd — FDA 483 Findings

US FDAInspected 2023-12-08Published 2026-11-05 4 findingsLaboratory and QC controlsQuality unit oversightEquipment and facilityMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

The firm’s stability program was inadequate in that the firm’s QC Laboratory failed to utilize a stability indicating method for assay testing of(b) (4) The QC Laboratory utilizes a titration method for assay testing of (b) (4) for all stability testing that the firm has conducted on their(B) (4) API products including the following US marketed API:(B) (4) For example, the firm utilized the titration assay method for the accelerated stability studies of(D) (4) API (lot#s(b) (4) The data from the accelerated stability studies was later utilized to determine the shelf life of the product.

2Quality unit oversight

The firm's Production Unit utilizes critical raw materials within the manufacturing process prior to the completion of identification testing and release of the raw materials by the firm's Quality Control Unit.

3Equipment and facility

Equipment and utensils utilized in the production of API for the US Market are not cleaned or maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, purity and quality of the drug substance.

4Material and supplier control

Verification testing of the raw material supplier COA is inadequate as the firm has failed to conduct all of the analyses listed on the respective supplier COA.

A record as of the US FDA document published on 2026-11-05. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Titan Kogyo, Ltd company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.